drugset / Trial / NCT05895370
HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors
Phase 1
Unknown
12 enrolled
BGI, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this protocol is to evaluate the feasibility and safety of HPV-T in HPV 16 positive recurrent or metastatic solid tumor patients.
Timeline
- Start
- 2023-04-13
- Primary completion
- 2024-12-13
- Completion
- 2025-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HPV-T | Cell therapy | 5e+09 cells | Intravenous |
| Subject | HPV-T | Cell therapy | 1.5e+10 cells | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | 500000 unknown | Subcutaneous |